TRACON Pharmaceuticals, Inc. (TCON) Reaches $2.90 After 8.00% Down Move; Howe & Rusling Has Boosted United Technologies (UTX) Stake

December 6, 2017 - By Marguerite Chambers

The stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) is a huge mover today! The stock decreased 4.92% or $0.15 during the last trading session, reaching $2.9. About 84,835 shares traded. TRACON Pharmaceuticals,

Inc. (NASDAQ:TCON) has declined 52.06% since December 6, 2016 and is downtrending. It has underperformed by 68.76% the S&P500.The move comes after 6 months negative chart setup for the $50.79 million company. It was reported on Dec, 6 by Barchart.com. We have $2.67 PT which if reached, will make NASDAQ:TCON worth $4.06M less.

Howe & Rusling Inc increased United Technologies Corp (UTX) stake by 79.98% reported in 2017Q2 SEC filing. Howe & Rusling Inc acquired 3,029 shares as United Technologies Corp (UTX)’s stock rose 8.03%. The Howe & Rusling Inc holds 6,816 shares with $832,000 value, up from 3,787 last quarter. United Technologies Corp now has $96.74B valuation. The stock increased 0.71% or $0.85 during the last trading session, reaching $121.14. About 728,646 shares traded. United Technologies Corporation (NYSE:UTX) has risen 22.99% since December 6, 2016 and is uptrending. It has outperformed by 6.29% the S&P500.

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc has $18 highest and $10 lowest target. $15.33’s average target is 428.62% above currents $2.9 stock price. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. On Wednesday, July 29 the stock rating was initiated by Roth Capital with “Buy”. TH Capital initiated the stock with “Buy” rating in Wednesday, July 29 report. Jefferies initiated the stock with “Buy” rating in Wednesday, December 21 report. Zacks upgraded the shares of TCON in report on Friday, September 4 to “Hold” rating.

Analysts await TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report earnings on February, 27. They expect $-0.45 EPS, 0.00% or $0.00 from last year’s $-0.45 per share. After $0.07 actual EPS reported by TRACON Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -742.86% negative EPS growth.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $50.79 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It currently has negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

Howe & Rusling Inc decreased Schwab Charles Corp New (NYSE:SCHW) stake by 11,663 shares to 139,850 valued at $6.01M in 2017Q2. It also reduced Mohawk Inds Inc (NYSE:MHK) stake by 22,536 shares and now owns 159 shares. Dell Technologies Inc was reduced too.

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It is negative, as 39 investors sold UTX shares while 553 reduced holdings. 112 funds opened positions while 451 raised stakes. 611.76 million shares or 0.92% less from 617.43 million shares in 2017Q1 were reported. 22,240 were reported by Aull And Monroe Investment Mngmt Corp. Legal General Grp Public Ltd Co reported 0.37% of its portfolio in United Technologies Corporation (NYSE:UTX). Putnam Invests Limited Liability invested 0.35% of its portfolio in United Technologies Corporation (NYSE:UTX). Capital Fund Mgmt owns 40,745 shares for 0.04% of their portfolio. Denver Inv Ltd accumulated 2,425 shares or 0.01% of the stock. Ontario Teachers Pension Plan Board reported 0.16% in United Technologies Corporation (NYSE:UTX). Acropolis Invest Mngmt holds 0.19% or 9,327 shares in its portfolio. The Virginia-based Kanawha Capital Management Limited Liability Corporation has invested 2.4% in United Technologies Corporation (NYSE:UTX). Canal Ins Commerce reported 79,150 shares or 3.53% of all its holdings. Brighton Jones Ltd Co reported 7,131 shares. Quantitative Systematic Strategies Ltd Liability Com holds 0.15% in United Technologies Corporation (NYSE:UTX) or 4,766 shares. Riverhead Management Limited Liability Corporation accumulated 0.08% or 13,354 shares. Df Dent & Communications invested in 0.01% or 4,070 shares. Mufg Americas Corporation accumulated 107,919 shares. Guardian Life Insurance Of America has invested 0.03% in United Technologies Corporation (NYSE:UTX).

Among 21 analysts covering United Technologies Corporation (NYSE:UTX), 7 have Buy rating, 0 Sell and 14 Hold. Therefore 33% are positive. United Technologies Corporation had 67 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Equalweight” rating given on Wednesday, July 27 by Barclays Capital. The company was maintained on Tuesday, December 15 by RBC Capital Markets. Cowen & Co maintained United Technologies Corporation (NYSE:UTX) on Tuesday, July 25 with “Buy” rating. The stock of United Technologies Corporation (NYSE:UTX) earned “Buy” rating by Argus Research on Wednesday, July 22. Robert W. Baird initiated United Technologies Corporation (NYSE:UTX) on Thursday, October 6 with “Neutral” rating. Jefferies maintained United Technologies Corporation (NYSE:UTX) rating on Friday, April 28. Jefferies has “Buy” rating and $132 target. The stock of United Technologies Corporation (NYSE:UTX) has “Neutral” rating given on Thursday, October 8 by JP Morgan. The stock of United Technologies Corporation (NYSE:UTX) has “Buy” rating given on Friday, July 7 by Jefferies. The rating was upgraded by Atlantic Securities to “Overweight” on Tuesday, December 5. The stock of United Technologies Corporation (NYSE:UTX) earned “Neutral” rating by Citigroup on Monday, October 10.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>